Last reviewed · How we verify

Planned Parenthood League of Massachusetts — Portfolio Competitive Intelligence Brief

Planned Parenthood League of Massachusetts pipeline: 0 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Mifepristone plus two doses Misoprostol Mifepristone plus two doses Misoprostol phase 3 Progesterone receptor antagonist + prostaglandin analog combination Progesterone receptor (PR); prostaglandin E1 receptor (EP receptor) Reproductive Health / Obstetrics
Mifepristone plus one dose Misoprostol Mifepristone plus one dose Misoprostol phase 3 Progesterone antagonist + prostaglandin analog Progesterone receptor (PR) + prostaglandin E1 receptor (EP receptor) Reproductive Health / Obstetrics

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Gynuity Health Projects · 1 shared drug class
  2. Hadassah Medical Organization · 1 shared drug class
  3. Reproductive Health Training Center of the Republic of Moldova · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Planned Parenthood League of Massachusetts:

Cite this brief

Drug Landscape (2026). Planned Parenthood League of Massachusetts — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/planned-parenthood-league-of-massachusetts. Accessed 2026-05-17.

Related